Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to -$1.8 million.

  • Arcutis Biotherapeutics' Free Cash Flow rose 94.96% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.2 million, marking a year-over-year increase of 80.19%. This contributed to the annual value of -$112.3 million for FY2024, which is 54.62% up from last year.
  • Arcutis Biotherapeutics' Free Cash Flow amounted to -$1.8 million in Q3 2025, which was down 813.01% from $246,000 recorded in Q2 2025.
  • Arcutis Biotherapeutics' Free Cash Flow's 5-year high stood at $246,000 during Q2 2025, with a 5-year trough of -$80.4 million in Q1 2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$34.8 million (2024), whereas its average is -$35.7 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Free Cash Flow crashed by 122.11% in 2021 and then skyrocketed by 100.55% in 2025.
  • Arcutis Biotherapeutics' Free Cash Flow (Quarterly) stood at -$52.0 million in 2021, then plummeted by 36.98% to -$71.2 million in 2022, then increased by 20.98% to -$56.2 million in 2023, then surged by 98.67% to -$748,000 in 2024, then surged by 94.96% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, $246,000 for Q2 2025, and -$31.0 million during Q1 2025.